-
公开(公告)号：EP3235819A1
公开(公告)日：2017-10-25
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
摘要翻译： 本申请涉及药物化学领域，特别涉及通式（I）所示的吡咯并嘧啶化合物，其立体异构体或其药学上可接受的盐。 本发明还涉及通式（I）代表的吡咯并嘧啶化合物的制备方法，药物组合物和吡咯并嘧啶化合物在治疗由Janus激酶介导的疾病中的用途。
-
公开(公告)号：EP3444237B1
公开(公告)日：2020-10-28
申请号：EP17769433.8
申请日：2017-03-22
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , YANG, Yanqing , DAI, Liguang , DUAN, Xiaowei , YANG, Zhao , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D203/24 , A61K31/396 , A61P35/00
-
公开(公告)号：EP3434671A1
公开(公告)日：2019-01-30
申请号：EP17769434.6
申请日：2017-03-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , DUAN, Xiaowei , DAI, Liguang , YANG, Zhao , YANG, Yanqing , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D275/02 , A61K31/425 , A61K31/433 , A61P35/00
摘要： Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
-
公开(公告)号：EP3235819B1
公开(公告)日：2020-11-18
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
-
5.发明公开
公开(公告)号：EP3533796A1
公开(公告)日：2019-09-04
申请号：EP17863410.1
申请日：2017-10-27
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , HU, Yuandong , WU, Wei , DAI, Liguang , DUAN, Xiaowei , YANG, Yanqing , SUN, Yinghui , HAN, Yongxin , PENG, Yong , KONG, Fansheng , LUO, Hong , YANG, Ling , XU, Hongjiang , GUO, Meng , ZHONG, Zhaobai , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377
摘要： Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
-
公开(公告)号：EP3434671B1
公开(公告)日：2020-10-21
申请号：EP17769434.6
申请日：2017-03-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , DUAN, Xiaowei , DAI, Liguang , YANG, Zhao , YANG, Yanqing , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： A61K31/425 , A61K31/433 , A61P35/00 , C07D275/03 , C07D285/10 , A61P35/02
-
公开(公告)号：EP3444237A1
公开(公告)日：2019-02-20
申请号：EP17769433.8
申请日：2017-03-22
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , YANG, Yanqing , DAI, Liguang , DUAN, Xiaowei , YANG, Zhao , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D203/24 , A61K31/396 , A61P35/00
摘要： An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation- induced cancer.
-
8.发明公开
公开(公告)号：EP3434676A1
公开(公告)日：2019-01-30
申请号：EP17769492.4
申请日：2017-03-27
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： WANG, Shulong , CHEN, Kuncheng , LIU, Xijie , HU, Yuandong , LIU, Bo , PENG, Yong , LUO, Hong , HAN, Yongxin , WANG, Shanchun , LIU, Mei , XU, Hongjiang
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
摘要： The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
-
公开(公告)号：EP3858832A1
公开(公告)日：2021-08-04
申请号：EP19878278.1
申请日：2019-10-29
发明人： LIU, Fei , FENG, Weiwei , WANG, Bin , XU, Hongjiang , WANG, Jinan , ZHANG, Xiquan , WANG, Shanchun , LIU, Yanlong , ZHANG, Jianqing , YAO, Yiyan , TANG, Xujing , SHI, Wei , ZHANG, Hongying , LI, Yang , TANG, Song , ZHU, Yizhong , LIU, Limin , GU, Hongmei , YANG, Ling
IPC分类号： C07D471/04 , C07D211/96 , C07D215/20 , A61K31/404 , A61P35/00
摘要： Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
-
10.发明公开
公开(公告)号：EP3443954A1
公开(公告)日：2019-02-20
申请号：EP17781942.2
申请日：2017-04-14
发明人： GU, Hongmei , WANG, Shanchun , ZHANG, Xiquan , HUANG, Lei , XU, Hongjiang , SONG, Wei , DONG, Ping , SUN, Zhongying , ZHANG, Ying , CHEN, Deyang
IPC分类号： A61K9/72 , A61K9/12 , A61K31/704 , A61P1/16 , A61P31/12
摘要： The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.018 秒)
